Cancer of Unknown Primary Diagnostics Are Advancing
Despite limited progress in prognosis, recent advancements in molecular diagnostics is transforming diagnosis of cancer of unknown primary.
Category: Unknown Origin & Other Cancer Types
Unknown Origin & Other Cancer Types
Latest
Unknown Origin & Other Cancer Types
Latest
FDA Approves Roche’s HER2 Companion Diagnostic for Biliary Tract Cancer Treatment
The PATHWAY HER2 test is a CDx for HER2-positive biliary tract cancer for targeted treatment with Jazz Pharmaceuticals' ZIIHERA.
Unknown Origin & Other Cancer Types
Latest
Researchers Develop Affordable, Rapid Blood Test for Brain Cancer
A new automated device can diagnose glioblastoma in under an hour using a novel electrokinetic biochip that detects active EGFRs from blood.
Researchers Identify Biomarker Linked to Renal Cancer Recurrence
Researcher identified a 15-gene signature biomarker that can stratify renal cancer patients into low or high risk of recurrence.
Read More
Rapid Cerebrospinal Fluid Test Decreases Time for Brain Tumors Diagnosis
A new genotyping test using cerebrospinal fluid can rapidly diagnose brain cancers, reducing the need for invasive biopsies.
Read More
New Biomarker Helps Detect Ovarian Cancer Years Before Conventional Diagnosis
Researchers discovered a novel immune-based biomarker that could pave the way for potential early detection of high-grade ovarian cancer.
Read More
Multi-Analyte Blood Test Outperforms Ultrasound in Early Liver Cancer Detection
A clinical trial shows that a Helio Genomics test outperforms ultrasound in detecting hepatocellular carcinoma in liver cirrhosis patients.
Read More
New Saliva-Based Test to Diagnose Oral Cavity CancerÂ
Salignostics has partnered with ARC Innovation at Sheba Medical Center to develop a saliva-based test for detecting oral cavity cancer.
Read More
Ovarian Cancer Detection Method Improvement Over CA125
Mercy BioAnalytics will present data showing that their Mercy Halo test significantly improves early detection of ovarian cancer.
Read More
New Biomarkers Identified for Improve Renal Cancer Diagnosis
Researchers discovered new biomarkers for renal cell carcinomas, enhancing the diagnosis of various subtypes.
Read More
Leptomeningeal Cancer Cell Diagnostic Assay Gets Clinical Trial Implementation
The tumor cell enumeration assay is a diagnostic test that is promising for establishing the diagnosis of leptomeningeal metastases.
Read More
Myriad Genetics Receives Patent for High-Definition MRD Assay
The U.S. Patent and Trademark Office issued a patent to Myriad Genetics aimed at strengthening its ability to deliver a MRD assay to market.Â
Read More
New Test Could Identify Aggressive Ovarian Cancers Early
A new algorithm may help identify high-risk precancerous lesions on the fallopian tubes thought to lead to a common form of ovarian cancer
Read More
Bladder Cancer LDT Receives Medicare Coverage
The Oncuria Bladder Cancer Tests, a DiaCarta validated lab developed test (LDT), received Medicare coverage effective Jan. 1, 2024.
Read More
New Terahertz Biosensor Detects Skin Cancer with High Accuracy
Researchers have developed a new biosensor using terahertz waves that can detect skin cancer with improved sensitivity.
Read More
Lucid Diagnostics Contracts to Cover Esophageal Precancer Testing for 9/11 Responders and Survivors
Lucid Diagnostics has contracted with the World Trade Center Health Program to provide the EsoGuard Esophageal DNA test as a covered benefit.
Read More
Sophia Genetics and AstraZeneca Spain to Increase Ovarian Cancer Testing in Spain
The program started in 2022 when AstraZeneca and Sophia Genetics collaborated to deploy HRD testing to five labs throughout the country.
Read More
Researchers Leverage AI for Early Diagnostic Test for Ovarian Cancer
Scientists combined machine learning with info on blood metabolites to develop a new test able to detect ovarian cancer with 93% accuracy.
Read More